CN Patent

CN101242827A — 包含奈必洛尔的组合物

Assigned to Mylan Inc · Expires 2008-08-13 · 18y expired

What this patent protects

已显示奈必洛尔在心血管疾病如高血压、充血性心力衰竭、动脉硬化和内皮功能障碍的治疗中是有益的。本发明特征在于一种药物组合物，它包含奈必洛尔和至少一种其它活性剂，其中至少一种其它活性剂是心血管药。

USPTO Abstract

已显示奈必洛尔在心血管疾病如高血压、充血性心力衰竭、动脉硬化和内皮功能障碍的治疗中是有益的。本发明特征在于一种药物组合物，它包含奈必洛尔和至少一种其它活性剂，其中至少一种其它活性剂是心血管药。

Drugs covered by this patent

Patent Metadata

Patent number: CN101242827A
Jurisdiction: CN
Classification: —
Expires: 2008-08-13
Drug substance claim: No
Drug product claim: No
Assignee: Mylan Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.